Allergan plc (AGN) Holdings Trimmed by YorkBridge Wealth Partners LLC

YorkBridge Wealth Partners LLC lessened its position in shares of Allergan plc (NYSE:AGN) by 30.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,563 shares of the company’s stock after selling 1,137 shares during the quarter. YorkBridge Wealth Partners LLC’s holdings in Allergan were worth $423,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in AGN. Standard Life Aberdeen plc boosted its holdings in shares of Allergan by 1.2% during the 4th quarter. Standard Life Aberdeen plc now owns 879,056 shares of the company’s stock worth $143,861,000 after buying an additional 10,579 shares in the last quarter. Pinnacle Associates Ltd. boosted its holdings in shares of Allergan by 10.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 86,045 shares of the company’s stock worth $14,075,000 after buying an additional 8,322 shares in the last quarter. Golub Group LLC boosted its holdings in shares of Allergan by 24.0% during the 4th quarter. Golub Group LLC now owns 279,473 shares of the company’s stock worth $45,716,000 after buying an additional 54,169 shares in the last quarter. State of Tennessee Treasury Department boosted its holdings in shares of Allergan by 8.9% during the 4th quarter. State of Tennessee Treasury Department now owns 257,417 shares of the company’s stock worth $42,108,000 after buying an additional 20,956 shares in the last quarter. Finally, Alexandria Capital LLC boosted its holdings in shares of Allergan by 61,075.0% during the 4th quarter. Alexandria Capital LLC now owns 4,894 shares of the company’s stock worth $800,000 after buying an additional 4,886 shares in the last quarter. 79.66% of the stock is owned by institutional investors and hedge funds.

In related news, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction on Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Brent L. Saunders acquired 4,600 shares of the company’s stock in a transaction on Wednesday, December 6th. The shares were bought at an average price of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 17,630 shares of company stock worth $2,890,057. Company insiders own 0.36% of the company’s stock.

AGN has been the topic of a number of research analyst reports. Zacks Investment Research cut Allergan from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. TheStreet cut Allergan from a “c-” rating to a “d+” rating in a report on Monday, December 4th. Morgan Stanley set a $200.00 price target on Allergan and gave the stock a “buy” rating in a report on Wednesday, December 6th. Deutsche Bank restated a “buy” rating and set a $215.00 price target on shares of Allergan in a report on Tuesday, January 9th. Finally, Vetr upgraded Allergan from a “sell” rating to a “hold” rating and set a $189.60 price target on the stock in a report on Friday, January 26th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $227.23.

Shares of Allergan plc (NYSE AGN) traded up $0.30 on Thursday, hitting $159.61. The company had a trading volume of 118,233 shares, compared to its average volume of 3,058,037. Allergan plc has a 12 month low of $156.00 and a 12 month high of $256.80. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41. The company has a market cap of $52,620.00, a PE ratio of -13.33, a P/E/G ratio of 1.14 and a beta of 1.19.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. During the same period last year, the business earned $3.90 EPS. The business’s revenue was up 12.0% on a year-over-year basis. analysts anticipate that Allergan plc will post 15.57 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.80%. Allergan’s dividend payout ratio (DPR) is -23.35%.

COPYRIGHT VIOLATION NOTICE: “Allergan plc (AGN) Holdings Trimmed by YorkBridge Wealth Partners LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/22/allergan-plc-agn-holdings-trimmed-by-yorkbridge-wealth-partners-llc.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply